Fibroblast growth factor 23 (FGF23) and mortality: The Ludwigshafen Risk and Cardiovascular Health Study

被引:68
作者
Brandenburg, Vincent M. [1 ]
Kleber, Marcus E. [2 ]
Vervloet, Marc G. [3 ]
Tomaschitz, Andreas [4 ]
Pilz, Stefan [5 ,6 ,7 ]
Stojakovic, Tatjana [8 ]
Delgado, Graciela [2 ]
Grammer, Tanja B. [2 ]
Marx, Nikolaus [1 ]
Maerz, Winfried [2 ,8 ]
Scharnagl, Hubert [8 ,9 ]
机构
[1] Rhein Westfal TH Aachen, Dept Cardiol, Univ Hosp, D-52057 Aachen, Germany
[2] Heidelberg Univ, Med Fac Mannheim, Med Clin 5, Mannheim, Germany
[3] Vrije Univ Amsterdam, Med Ctr, Dept Nephrol, Amsterdam, Netherlands
[4] PV Bad Aussee, Specialist Clin Rehabil, Bad Aussee, Austria
[5] Med Univ Graz, Dept Cardiol, Graz, Austria
[6] Vrije Univ Amsterdam, Med Ctr, Dept Epidemiol & Biostat, Amsterdam, Netherlands
[7] Vrije Univ Amsterdam, Med Ctr, EMGO Inst Hlth & Care Res, Amsterdam, Netherlands
[8] Med Univ Graz, Clin Inst Med & Chem Lab Diagnost, Graz, Austria
[9] Synlab Ctr Lab Diagnost, Heidelberg, Germany
关键词
Coronary artery disease; Coronary angiography; Fibroblast growth factor 23; FGF23; Mortality; Cardiovascular events; Outcome-; phosphate; LEFT-VENTRICULAR HYPERTROPHY; MINERAL METABOLISM; PARATHYROID-HORMONE; ARTERY-DISEASE; HEART; EVENTS; FGF-23; PHOSPHORUS; PHOSPHATE; LEVEL;
D O I
10.1016/j.atherosclerosis.2014.08.037
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Fibroblast growth factor 23 (FGF23) is an important regulatory hormone in phosphate and vitamin D metabolism. Here, we investigated the associations of FGF23 with traditional cardiovascular risk factors and with bone metabolism parameters as well as the impact of FGF23 upon long-term mortality in a large cohort of patients referred for coronary angiography. Methods: We examined whether c-term FGF23 concentrations at baseline were associated with cardiovascular and total mortality in 2974 patients from the Ludwigshafen Risk and Cardiovascular Health Study (LURIC). We investigated if these associations were independent from established cardiovascular risk factors as well as from other mineral regulating factors and bone biomarkers such as calcium, parathyroid hormone (PTH), alkaline phosphatase (AP), vitamin D, and serum phosphate. Results: Mean age of participants was 63 +/- 10 years; median c-term FGF23 serum levels were 54 (40-78) RU/ml. During a median follow-up of 9.9 years, 884 deaths (30%) occurred, 545 (18%) of which were cardiovascular. FGF23 significantly and inversely correlated with eGFR. AP, phosphate, and PTH increased in parallel with quartiles of FGF23. Age-and sex-adjusted hazard ratios (HRs) in the fourth quartile compared to the first quartile of FGF23 were 2.54 (95% CI, 2.09-3.09; p < 0.001) for all cause and 2.56 (95% CI, 1.99-3.28; p < 0.001) for cardiovascular mortality. These associations remained significant after additional adjustments for cardiovascular risk factors and bone biomarkers (calcium, PTH, AP, vitamin D, and phosphate): Adjusted HRs were 1.38 (95% CI, 1.26-1.52; p < 0.001) for all-cause and 1.35 (95% CI, 1.20-1.52; p < 0.001) for cardiovascular mortality for each increase by one standard deviation of c-term FGF23. Conclusions: In patients undergoing coronary angiography baseline c-term FGF23 levels predict the risk for all-cause and cardiovascular mortality over 9.9 years of follow-up. These associations were independent of established cardiovascular risk factors and serum phosphate. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:53 / 59
页数:7
相关论文
共 27 条
[1]   Serum FGF23 and Risk of Cardiovascular Events in Relation to Mineral Metabolism and Cardiovascular Pathology [J].
Arnlov, Johan ;
Carlsson, Axel C. ;
Sundstrom, Johan ;
Ingelsson, Erik ;
Larsson, Anders ;
Lind, Lars ;
Larsson, Tobias E. .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2013, 8 (05) :781-786
[2]   Mineral metabolism, mortality, and morbidity in maintenance hemodialysis [J].
Block, GA ;
Klassen, PS ;
Lazarus, JM ;
Ofsthun, N ;
Lowrie, EG ;
Chertow, GM .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (08) :2208-2218
[3]   The role of vitamin D in cardiovascular disease: From present evidence to future perspectives [J].
Brandenburg, Vincent M. ;
Vervloet, Marc G. ;
Marx, Nikolaus .
ATHEROSCLEROSIS, 2012, 225 (02) :253-263
[4]   25-Hydroxyvitamin D Levels and Risk of Ischemic Heart Disease, Myocardial Infarction, and Early Death Population-Based Study and Meta-Analyses of 18 and 17 Studies [J].
Brondum-Jacobsen, Peter ;
Benn, Marianne ;
Jensen, Gorm B. ;
Nordestgaard, Borge G. .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2012, 32 (11) :2794-+
[5]   FGF23 induces left ventricular hypertrophy [J].
Faul, Christian ;
Amaral, Ansel P. ;
Oskouei, Behzad ;
Hu, Ming-Chang ;
Sloan, Alexis ;
Isakova, Tamara ;
Gutierrez, Orlando M. ;
Aguillon-Prada, Robier ;
Lincoln, Joy ;
Hare, Joshua M. ;
Mundel, Peter ;
Morales, Azorides ;
Scialla, Julia ;
Fischer, Michael ;
Soliman, Elsayed Z. ;
Chen, Jing ;
Go, Alan S. ;
Rosas, Sylvia E. ;
Nessel, Lisa ;
Townsend, Raymond R. ;
Feldman, Harold I. ;
Sutton, Martin St. John ;
Ojo, Akinlolu ;
Gadegbeku, Crystal ;
Di Marco, Giovana Seno ;
Reuter, Stefan ;
Kentrup, Dominik ;
Tiemann, Klaus ;
Brand, Marcus ;
Hill, Joseph A. ;
Moe, Orson W. ;
Kuro-o, Makoto ;
Kusek, John W. ;
Keane, Martin G. ;
Wolf, Myles .
JOURNAL OF CLINICAL INVESTIGATION, 2011, 121 (11) :4393-4408
[6]  
Friesinger G C, 1970, Trans Assoc Am Physicians, V83, P78
[7]   Fibroblast growth factor 23, the ankle-brachial index, and incident peripheral artery disease in the Cardiovascular Health Study [J].
Garimella, Pranav S. ;
Ix, Joachim H. ;
Katz, Ronit ;
Chonchol, Michel B. ;
Kestenbaum, Bryan R. ;
de Boer, Ian H. ;
Siscovick, David S. ;
Shastri, Shani ;
Hiramoto, Jade S. ;
Shlipak, Michael G. ;
Sarnak, Mark J. .
ATHEROSCLEROSIS, 2014, 233 (01) :91-96
[8]   Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis [J].
Gutierrez, Orlando M. ;
Mannstadt, Michael ;
Isakova, Tamara ;
Rauh-Hain, Jose Alejandro ;
Tamez, Hector ;
Shah, Anand ;
Smith, Kelsey ;
Lee, Hang ;
Thadhani, Ravi ;
Juppner, Harald ;
Wolf, Myles .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (06) :584-592
[9]   Fibroblast Growth Factor 23, Cardiovascular Disease Risk Factors, and Phosphorus Intake in the Health Professionals Follow-up Study [J].
Gutierrez, Orlando M. ;
Wolf, Myles ;
Taylor, Eric N. .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2011, 6 (12) :2871-2878
[10]   Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney Disease [J].
Gutierrez, Orlando M. ;
Januzzi, James L. ;
Isakova, Tamara ;
Laliberte, Karen ;
Smith, Kelsey ;
Collerone, Gina ;
Sarwar, Ammar ;
Hoffmann, Udo ;
Coglianese, Erin ;
Christenson, Robert ;
Wang, Thomas J. ;
deFilippi, Christopher ;
Wolf, Myles .
CIRCULATION, 2009, 119 (19) :2545-2552